Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 11: Drugs and Performance-Enhancing Substances

Eligibility and Disqualification Recommendations for Athletes with Cardiovascular Abnormalities

Preamble: Principles, and General Considerations

Task Force 1: Classification of Sports: Dynamic, Static and Impact

Task Force 2: Preparticipation Screening for Cardiovascular Disease in Competitive Athletes

Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis

Task Force 4: Congenital Heart Disease

Task Force 6: Hypertension

Task Force 7: Aortic Diseases, Including Marfan Syndrome

Task Force 8: Coronary Artery Disease

Task Force 9: Arrhythmias and Conduction Defects

Task Force 10: The Cardiac Channelopathies

Task Force 11: Drugs and Performance Enhancing Substances

Task Force 12: Emergency Action Plans, Resuscitation, CPR, and AEDs

Task Force 13: Commotio Cordis

Task Force 14: Sickle Cell Trait

Task Force 15: Legal Aspects of Medical Eligibility and Disqualification Recommendations

Top Things to Know: Eligibility and Disqualification Recommendations for Athletes with Cardiovascular Abnormalities

Video: Recommendations for Competitive Athletes With Cardiovascular Abnormalities

Eligibility and Disqualification Recommendations for Athletes with Cardiovascular Abnormalities